Excerpt from Hemorrhagic Disease of NewbornSynonyms, Key Words, and Related Terms: hemorrhagic disease of newborn, HDN, vitamin K deficiency bleeding, VKDB, coagulopathy, intracranial hemorrhage, ICH, late-onset VKDB, early-onset VKDB, classic VKDB Please click here to view the full topic text: Hemorrhagic Disease of NewbornBackgroundThe more appropriate term for hemorrhagic disease of newborn is vitamin K deficiency bleeding (VKDB). Historically, all bleeding disorders in the newborn were grouped together under the diagnosis of hemorrhagic disease of the newborn (HDN). With methods available today for the accurate diagnosis of other factor deficiency states and immune thrombocytopenias, VKDB can be distinguished from other disorders by exclusion and appropriate analysis of these other factors involved in coagulation. Vitamin K is a fat-soluble vitamin that can be absorbed from the GI tract in the presence of bile salts. Vitamin K is required for the production of coagulation factors II, VII, IX, and X in the liver. Because of the short half-life of these factors, and the small amounts of vitamin K that can be stored in the body, inadequate intake of vitamin K can result in deficiency in a short period of time. PIVKA, inactive precursor proteins induced in vitamin K's absence, are measurable and can be used as an indicator of vitamin K deficiency. The 3 forms of vitamin K are as follows:
PathophysiologyNewborns are relatively vitamin K deficient for a variety of reasons. Factors that can contribute to this deficiency include low vitamin K stores at birth, poor placental transfer of vitamin K, low levels of vitamin K in breast milk, and sterility of the gut. Because standard commercial infant formulas contain supplemental vitamin K, VKDB is almost exclusively a problem of breastfed infants. Infants with inadequate intake are at higher risk. The most common sites of bleeding are the umbilicus, mucous membranes, GI tract, circumcision, and venipunctures. Hematomas at sites of trauma, such as large cephalohematomas and bruising, are also common findings. Intracranial bleeding can occur and is the main cause of mortality and long-term morbidity. FrequencyUnited StatesIn the United States, routine intramuscular administration of vitamin K immediately after birth has made VKDB an uncommon occurrence. The frequency of VKDB is variably reported, from 0.25-1.7% in the first week of life. The frequency in a given US population depends upon the frequency of breastfeeding. Late VKDB (2-12 wk) appears to be prevented with parenteral administration of vitamin K, as well. InternationalThe frequency of VKDB in countries outside the United States varies with the use of vitamin K prophylaxis, the efficacy of prophylaxis programs, frequency of breastfeeding, and the vitamin K content of locally available formulas. Late VKDB has fallen from 4.4-7.2/100,000 births to 1.4-6.4/100,000 births in reports from Asia and Europe after regimens for prophylaxis were instituted. Mortality/MorbidityIntracranial hemorrhage (ICH) is uncommon in classic VKDB but can be observed in more than 50% of infants with late-onset VKDB. ICH is responsible for nearly all mortality and all long-term sequelae resulting from VKDB. RaceNo racial predilection exists, but breastfeeding practices can result in apparent racial disparities. SexNo apparent sex predilection exists. AgeVKDB can occur in 3 general time frames.
Please click here to view the full topic text: Hemorrhagic Disease of Newborn |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |